JCR Pharmaceuticals Co., Ltd.

TSE:4552 Stock Report

Market Cap: JP¥77.5b

JCR Pharmaceuticals Valuation

Is 4552 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4552 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4552 (¥621) is trading below our estimate of fair value (¥916.02)

Significantly Below Fair Value: 4552 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4552?

Other financial metrics that can be useful for relative valuation.

4552 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA7.7x
PEG Ratio2.9x

Price to Earnings Ratio vs Peers

How does 4552's PE Ratio compare to its peers?

The above table shows the PE ratio for 4552 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.4x
4886 ASKA Pharmaceutical HoldingsLtd
9x-4.3%JP¥68.0b
4569 KYORIN Pharmaceutical
18.5x-12.5%JP¥98.5b
4559 Zeria Pharmaceutical
12.2x11.4%JP¥94.6b
4534 Mochida Pharmaceutical
25.9x15.2%JP¥117.9b
4552 JCR Pharmaceuticals
14.1x4.9%JP¥77.5b

Price-To-Earnings vs Peers: 4552 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (16.4x).


Price to Earnings Ratio vs Industry

How does 4552's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4552 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the JP Pharmaceuticals industry average (18.7x).


Price to Earnings Ratio vs Fair Ratio

What is 4552's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4552 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ratio16.5x

Price-To-Earnings vs Fair Ratio: 4552 is good value based on its Price-To-Earnings Ratio (14.1x) compared to the estimated Fair Price-To-Earnings Ratio (16.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4552 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥621.00
JP¥851.43
+37.1%
57.5%JP¥2,000.00JP¥560.00n/a7
Jul ’25JP¥614.00
JP¥851.43
+38.7%
57.5%JP¥2,000.00JP¥560.00n/a7
Jun ’25JP¥574.00
JP¥1,222.86
+113.0%
41.3%JP¥2,000.00JP¥560.00n/a7
May ’25JP¥813.00
JP¥1,557.14
+91.5%
17.8%JP¥2,000.00JP¥1,200.00n/a7
Apr ’25JP¥840.00
JP¥1,657.14
+97.3%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Mar ’25JP¥895.00
JP¥1,657.14
+85.2%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Feb ’25JP¥1,062.00
JP¥1,657.14
+56.0%
28.6%JP¥2,700.00JP¥1,200.00n/a7
Jan ’25JP¥1,172.00
JP¥1,842.86
+57.2%
27.2%JP¥2,700.00JP¥1,200.00n/a7
Dec ’24JP¥1,261.00
JP¥1,842.86
+46.1%
27.2%JP¥2,700.00JP¥1,200.00n/a7
Nov ’24JP¥1,130.00
JP¥1,857.14
+64.3%
27.4%JP¥2,700.00JP¥1,200.00n/a7
Oct ’24JP¥1,495.50
JP¥1,943.33
+29.9%
25.4%JP¥2,700.00JP¥1,300.00n/a6
Sep ’24JP¥1,268.50
JP¥1,901.43
+49.9%
26.4%JP¥2,800.00JP¥1,300.00n/a7
Aug ’24JP¥1,378.00
JP¥1,901.43
+38.0%
26.4%JP¥2,800.00JP¥1,300.00n/a7
Jul ’24JP¥1,269.00
JP¥2,007.14
+58.2%
26.8%JP¥2,800.00JP¥1,300.00JP¥614.007
Jun ’24JP¥1,377.00
JP¥2,185.71
+58.7%
25.1%JP¥2,900.00JP¥1,300.00JP¥574.007
May ’24JP¥1,451.00
JP¥2,412.50
+66.3%
20.8%JP¥2,900.00JP¥1,300.00JP¥813.008
Apr ’24JP¥1,413.00
JP¥2,412.50
+70.7%
20.8%JP¥2,900.00JP¥1,300.00JP¥840.008
Mar ’24JP¥1,423.00
JP¥2,475.00
+73.9%
16.5%JP¥2,900.00JP¥1,700.00JP¥895.008
Feb ’24JP¥1,636.00
JP¥2,562.50
+56.6%
20.8%JP¥3,400.00JP¥1,700.00JP¥1,062.008
Jan ’24JP¥1,681.00
JP¥2,673.75
+59.1%
18.6%JP¥3,400.00JP¥1,700.00JP¥1,172.008
Dec ’23JP¥1,919.00
JP¥2,736.25
+42.6%
22.1%JP¥3,900.00JP¥1,700.00JP¥1,261.008
Nov ’23JP¥2,097.00
JP¥2,811.25
+34.1%
17.8%JP¥3,900.00JP¥2,300.00JP¥1,130.008
Oct ’23JP¥2,165.00
JP¥3,077.50
+42.1%
17.6%JP¥3,900.00JP¥2,300.00JP¥1,495.508
Sep ’23JP¥2,154.00
JP¥3,077.50
+42.9%
17.6%JP¥3,900.00JP¥2,300.00JP¥1,268.508
Aug ’23JP¥2,456.00
JP¥3,057.78
+24.5%
16.8%JP¥3,900.00JP¥2,300.00JP¥1,378.009
Jul ’23JP¥2,287.00
JP¥2,857.00
+24.9%
24.1%JP¥3,900.00JP¥1,500.00JP¥1,269.0010

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.